Akeso's (HKG:9926) board approved a plan for a trustee to buy back up to HK$200 million ordinary shares under a 2021 restricted share unit scheme, according to a Thursday Hong Kong bourse filing.
The shares will be repurchased from the open market, the drug company said.
Additionally, Chairperson and CEO Xia Yu, Chief Financial Officer Bing C. Wang, and three executive directors plan to increase their shareholdings in the company.
The parties will purchase a total of up to HK$50 million shares from the open market.